Kempharm Stock Target Price and Analyst Consensus

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

The current analyst and expert consensus on Kempharm is Buy, with 0 strong sell and 1 strong buy opinions. The current projected Kempharm target price consensus is 19.0 with 2 analyst opinions. The most common way Kempharm analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Kempharm executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Kempharm. We encourage you to use your own analysis of Kempharm to validate this buy or sell advice. Kempharm buy-or-sell recommendation module provides average expert sentiment on the projected Kempharm target price to derive its highest and lowest estimates based on projected price volatility of 12.727. Please see Macroaxis Advice on Kempharm to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.

Search Analyst Recommendations 

 
Refresh
The current Gross Profit is estimated to increase to about 14.6 M, while Profit Margin is projected to decrease to (1.04) . Kempharm Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 2.83 Million. The current Cash and Equivalents is estimated to increase to about 4.4 M, while Debt Non Current is projected to decrease to roughly 68.9 M.

Kempharm Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kempharm target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kempharm target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Number of Opinions2
Lowered Outlook0
Raized Outlook0
Buy
Most Kempharm analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Kempharm stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kempharm, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Kempharm Target Price Projection

Kempharm's current and average target prices are 10.75 and 19.00, respectively. The current price of Kempharm is the price at which Kempharm is currently trading. On the other hand, Kempharm's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Kempharm Market Quote on 29th of July 2021

Low Price10.57Odds
High Price11.03Odds

10.75

Target Price

Analyst Consensus On Kempharm Target Price

Low Estimate10.0Odds
High Estimate28.0Odds
Number of Analysts2
Standard Deviation12.727

19.0

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Kempharm and the information provided on this page.

Kempharm Analyst Ratings

Kempharm's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Kempharm stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Kempharm's financials, market performance, and future outlook by experienced professionals. Kempharm's historical ratings below, therefore, can serve as a valuable tool for investors.

Average Consensus Estimates

About Kempharm Target Price Projections

Kempharm's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as Kempharm and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now. Generally, the target price of Kempharm depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Kempharm

Additional Kempharm Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Kempharm is a key component of Kempharm valuation and have some predictive power on the future returns of a Kempharm.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Kempharm's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Kempharm in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
7.1010.6814.26
Details
Intrinsic
Valuation
LowReal ValueHigh
9.5213.1016.68
Details
Earnings
Estimates (2)
LowProjected EPSHigh
0.610.620.64
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Kempharm. Your research has to be compared to or analyzed against Kempharm's peers to derive any actionable benefits. When done correctly, Kempharm's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Kempharm.

Currently Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Macroaxis Index
Invested over 100 shares
Software
Invested a lot of shares
Momentum
Invested few shares
Please see Macroaxis Advice on Kempharm to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
The data published in Kempharm's official financial statements usually reflect Kempharm's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kempharm. For example, before you start analyzing numbers published by Kempharm accountants, it's critical to develop an understanding of what Kempharm's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Kempharm's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kempharm's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kempharm's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kempharm. Please utilize our Beneish M Score to check the likelihood of Kempharm's management to manipulate its earnings.